Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02207621 · ClinicalTrials.gov registry record · Phase 3
Evaluation of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma and Ocular Hypertension
A Phase 3 study of Ocular Hypertension and Open Angle Glaucoma, sponsored by Aerie Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 756
- Enrollment target
- 1
- Study location
NCT02207621: Completed Phase 3 study of Ocular Hypertension and Open Angle Glaucoma, sponsored by Aerie Pharmaceuticals.
NCT02207621 is a Phase 3 study of Ocular Hypertension and Open Angle Glaucoma that has completed, run by Aerie Pharmaceuticals. The registered enrollment target is 756 participants, above the 264-participant average among 54 other Ocular Hypertension trials with a reported enrollment target (186% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02207621, a Phase 3 study of Ocular Hypertension and Open Angle Glaucoma, has completed, sponsored by Aerie Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 756 participants
- Enrollment target
- 1
- Study location
Study Summary
Evaluation of the ocular hypotensive efficacy and safety of Netarsudil (AR-13324) Ophthalmic Solution compared to Timolol Maleate Ophthalmic Solution
Primary Outcome
The primary efficacy outcome is mean intraocular pressure (IOP)
Conditions Studied
Interventions
- OTHER Placebo
- DRUG AR-13324 Ophthalmic Solution 0.02%
- DRUG Timolol maleate Ophthalmic Solution 0.5% BID
- DRUG AR-13324 Ophthalmic Solution 0.02% BID
Study Locations (1)
New Jersey
- Aerie Pharmaceuticals - Bedminster
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 756 participants |
| Start Date | 2014-07 |
| Est. Completion | 2016-03 |
| Phase | Phase 3 |
What the finished NCT02207621 record still lists
NCT02207621 is an interventional study that assigns participants to a tested intervention. The registered 756 participants enrollment target is mid-sized for trials with a published cap, above the 264-participant average among 54 other Ocular Hypertension trials with a reported enrollment target (186% higher).
The record links to 2 conditions, with Ocular Hypertension appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.
NCT02207621 reports a single indexed study location in New Jersey.
Frequently Asked Questions
What is clinical trial NCT02207621 about?
NCT02207621 is a clinical study titled "Evaluation of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma and Ocular Hypertension". Evaluation of the ocular hypotensive efficacy and safety of Netarsudil (AR-13324) Ophthalmic Solution compared to Timolol Maleate Ophthalmic Solution
What is the current status of trial NCT02207621?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 756 participants. The study started on 2014-07. Estimated completion is 2016-03.
What conditions does trial NCT02207621 study?
This clinical trial studies the following conditions: Ocular Hypertension, Open Angle Glaucoma.
What interventions are being tested in trial NCT02207621?
The interventions under investigation include: Placebo (OTHER), AR-13324 Ophthalmic Solution 0.02% (DRUG), Timolol maleate Ophthalmic Solution 0.5% BID (DRUG), AR-13324 Ophthalmic Solution 0.02% BID (DRUG).
Who is sponsoring clinical trial NCT02207621?
This trial is sponsored by Aerie Pharmaceuticals, which has 32 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02207621 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ocular Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02207621's enrollment target sits among peer trials
756 2nd of 54 the highest of 54 other Ocular Hypertension trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Ocular Hypertension trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% and LUMIGAN® in the Treatment of Chronic Open-Angle Glaucoma or Ocular Hypertension in Both Eyes.
RECRUITING · Phase 3
-
Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhine)
RECRUITING · Phase 3
-
Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhone)
RECRUITING · Phase 3
-
Reformulated PG324 Ophthalmic Solution for Intraocular Pressure Reduction
ACTIVE NOT RECRUITING · Phase 3
-
Long-term Safety and Efficacy Extension Trial of Bimatoprost SR
ACTIVE NOT RECRUITING · Phase 3
-
Evaluation of Safety of SPARC0913 in Open Angle Glaucoma or Ocular Hypertension
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05869149 · 756 participants · NA
Systems Science Approaches to Improve Access to Healthier Foods: The FRESH Trial
- NCT06095583 · 756 participants · Phase 3
Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)
- NCT05379985 · 754 participants · Phase 1
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
- NCT05427370 · 754 participants · NA
The Canadian CABG or PCI in Patients With Ischemic Cardiomyopathy Trial (STICH3C)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia